- In December 2022, Gilead Sciences collaborated with ImmunoGen, Inc., a pioneer in antibody-drug conjugates (ADCs), to evaluate the safety and anti-leukemia activity of pivekimab sunirine, a CD123-targeting ADC, in combination with magrolimab, an investigational CD47 inhibitor. This study focuses on patients with relapsed or refractory CD123-positive acute myeloid leukemia (AML), aiming to leverage the complementary mechanisms of these therapies
- In October 2022, Gilead Sciences partnered with MacroGenics, a biopharmaceutical company specializing in monoclonal antibody-based cancer therapeutics. This collaboration focuses on the development of MGD024, an investigational bispecific antibody that targets CD3 and CD123 using MacroGenics’ proprietary DART® platform. MGD024 is designed to minimize cytokine-release syndrome while maintaining potent anti-tumor activity, offering a promising approach for treating hematologic malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)
- In October 2022, Bristol Myers Squibb entered into a strategic collaboration with Century Therapeutics, a biotechnology company specializing in advanced cell therapies. This agreement focuses on developing and commercializing up to four induced pluripotent stem cell (iPSC)-derived engineered natural killer (NK) cell and T cell programs. These programs target hematologic malignancies and solid tumors, leveraging Century's iPSC platform and Bristol Myers Squibb's expertise in oncology drug development
- In March 2022, Novartis entered into an agreement with Carisma Therapeutics, a biopharmaceutical company specializing in macrophage-based therapeutics, to manufacture the HER2-targeted CAR-M cell therapy. This therapy is being tested in early clinical trials for the treatment of solid tumors. The collaboration involves transferring Carisma's manufacturing process to Novartis' cell therapy site in Morris Plains, U.S., with clinical manufacturing planned to begin in 2023
- In March 2022, Teva Pharmaceuticals, a U.S.-based affiliate of Teva Pharmaceutical Industries Ltd., launched Revlimid, the generic version of lenalidomide capsules. This introduction provides patients with an essential treatment option for managing complex conditions such as multiple myeloma, certain myelodysplastic syndromes, and mantle cell lymphoma
